306 related articles for article (PubMed ID: 12450796)
1. Highly penetrant, rapid tumorigenesis through conditional inversion of the tumor suppressor gene Snf5.
Roberts CW; Leroux MM; Fleming MD; Orkin SH
Cancer Cell; 2002 Nov; 2(5):415-25. PubMed ID: 12450796
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation.
Isakoff MS; Sansam CG; Tamayo P; Subramanian A; Evans JA; Fillmore CM; Wang X; Biegel JA; Pomeroy SL; Mesirov JP; Roberts CW
Proc Natl Acad Sci U S A; 2005 Dec; 102(49):17745-50. PubMed ID: 16301525
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.
Kim KH; Roberts CW
Cancer Genet; 2014 Sep; 207(9):365-72. PubMed ID: 24853101
[TBL] [Abstract][Full Text] [Related]
4. The requirement for SNF5/INI1 in adipocyte differentiation highlights new features of malignant rhabdoid tumors.
Caramel J; Medjkane S; Quignon F; Delattre O
Oncogene; 2008 Mar; 27(14):2035-44. PubMed ID: 17922027
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.
McKenna ES; Tamayo P; Cho YJ; Tillman EJ; Mora-Blanco EL; Sansam CG; Koellhoffer EC; Pomeroy SL; Roberts CW
Cell Cycle; 2012 May; 11(10):1956-65. PubMed ID: 22544318
[TBL] [Abstract][Full Text] [Related]
6. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes to malignant rhabdoid tumors in mice.
Roberts CW; Galusha SA; McMenamin ME; Fletcher CD; Orkin SH
Proc Natl Acad Sci U S A; 2000 Dec; 97(25):13796-800. PubMed ID: 11095756
[TBL] [Abstract][Full Text] [Related]
7. Increased DNA damage sensitivity and apoptosis in cells lacking the Snf5/Ini1 subunit of the SWI/SNF chromatin remodeling complex.
Klochendler-Yeivin A; Picarsky E; Yaniv M
Mol Cell Biol; 2006 Apr; 26(7):2661-74. PubMed ID: 16537910
[TBL] [Abstract][Full Text] [Related]
8. SNF5/INI1 deficiency redefines chromatin remodeling complex composition during tumor development.
Wei D; Goldfarb D; Song S; Cannon C; Yan F; Sakellariou-Thompson D; Emanuele M; Major MB; Weissman BE; Kuwahara Y
Mol Cancer Res; 2014 Nov; 12(11):1574-85. PubMed ID: 25009291
[TBL] [Abstract][Full Text] [Related]
9. Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex.
Sen P; Luo J; Hada A; Hailu SG; Dechassa ML; Persinger J; Brahma S; Paul S; Ranish J; Bartholomew B
Cell Rep; 2017 Feb; 18(9):2135-2147. PubMed ID: 28249160
[TBL] [Abstract][Full Text] [Related]
10. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
11. Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.
Lee S; Cimica V; Ramachandra N; Zagzag D; Kalpana GV
Cancer Res; 2011 May; 71(9):3225-35. PubMed ID: 21521802
[TBL] [Abstract][Full Text] [Related]
12. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation.
Wang X; Lee RS; Alver BH; Haswell JR; Wang S; Mieczkowski J; Drier Y; Gillespie SM; Archer TC; Wu JN; Tzvetkov EP; Troisi EC; Pomeroy SL; Biegel JA; Tolstorukov MY; Bernstein BE; Park PJ; Roberts CW
Nat Genet; 2017 Feb; 49(2):289-295. PubMed ID: 27941797
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice.
DelBove J; Kuwahara Y; Mora-Blanco EL; Godfrey V; Funkhouser WK; Fletcher CD; Van Dyke T; Roberts CW; Weissman BE
Mol Carcinog; 2009 Dec; 48(12):1139-48. PubMed ID: 19676100
[TBL] [Abstract][Full Text] [Related]
14. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability.
McKenna ES; Sansam CG; Cho YJ; Greulich H; Evans JA; Thom CS; Moreau LA; Biegel JA; Pomeroy SL; Roberts CW
Mol Cell Biol; 2008 Oct; 28(20):6223-33. PubMed ID: 18710953
[TBL] [Abstract][Full Text] [Related]
15. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
16. Chromatin remodeling: from transcription to cancer.
Yaniv M
Cancer Genet; 2014 Sep; 207(9):352-7. PubMed ID: 24825771
[TBL] [Abstract][Full Text] [Related]
17. SMARCB1 deletion by a complex three-way chromosomal translocation in an extrarenal malignant rhabdoid tumor.
Bahrami A; Lee S; Caradine KD; Raimondi SC; Folpe AL
Cancer Genet; 2014 Sep; 207(9):437-40. PubMed ID: 25312828
[TBL] [Abstract][Full Text] [Related]
18. Activation of β-catenin/TCF targets following loss of the tumor suppressor SNF5.
Mora-Blanco EL; Mishina Y; Tillman EJ; Cho YJ; Thom CS; Pomeroy SL; Shao W; Roberts CW
Oncogene; 2014 Feb; 33(7):933-8. PubMed ID: 23435428
[TBL] [Abstract][Full Text] [Related]
19. Generation of a mouse model of atypical teratoid/rhabdoid tumor of the central nervous system through combined deletion of Snf5 and p53.
Ng JM; Martinez D; Marsh ED; Zhang Z; Rappaport E; Santi M; Curran T
Cancer Res; 2015 Nov; 75(21):4629-39. PubMed ID: 26363008
[TBL] [Abstract][Full Text] [Related]
20. Rhabdoid tumor predisposition syndrome.
Sredni ST; Tomita T
Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
